KCS

Precision medicine for solid cancer is targeted therapy based on scientific evidence such as pharmaceutic factor, gene, protein, and metabolite. Therefore, investigating accurate scientific evidence is critical for providing precision medicine for each patient. In general, scientific evidence was firstly investigated in the laboratory cell-based screening model. However, this model does not consider pharmacokinetics, structures, and microenvironments of solid cancer. Consequently, drugs efficacy or targeting biomarkers have shown discriminated results in clinical tests or therapy. Therefore, it is necessary to discover reliable biomarkers using pharmaceutical and biomimetic models at the pre-clinical level. Several clinical tests showed that the multidrug regimens have synergistic drug efficacy. However, the specific mechanisms of this effect and appropriate combinations of drugs are still ambiguous due to challenges at mimicry of pharmacokinetics and the tumor microenvironment at the laboratory level. We have constructed the pharmaceutical and biomimetic models with our Artificial Circulatory System for Tumoroid (ACST). Pharmacokinetic software, and microfluidic systems were used for the ACST systems. The results obtained from cutting-edge analysis techniques, including mass spectrometry (MS), ion mobility mass spectrometry (IM-MS), and spectroscopy, provided detailed drug action mechanisms based on the quantitative analyses.